

“Assessment of Pressor Effects of Drugs” A New

Therapeutic Innovation and Regulatory Science

52, 397-399

DOI: 10.1177/2168479018786478

Citation Report

#	ARTICLE	IF	CITATIONS
1	Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD. <i>Kidney International Reports</i> , 2021, 6, 2803-2810.	0.4	7